Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Down 22.4% in February

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 91,700 shares, a decrease of 22.4% from the February 13th total of 118,200 shares. Based on an average daily trading volume, of 310,600 shares, the short-interest ratio is presently 0.3 days. Currently, 6.4% of the shares of the stock are short sold.

Hedge Funds Weigh In On Mustang Bio

An institutional investor recently raised its position in Mustang Bio stock. Geode Capital Management LLC raised its stake in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 284,437 shares of the company’s stock after buying an additional 38,951 shares during the period. Geode Capital Management LLC owned about 29.63% of Mustang Bio worth $50,000 at the end of the most recent quarter. 9.95% of the stock is currently owned by institutional investors and hedge funds.

Mustang Bio Trading Down 0.8 %

Shares of NASDAQ:MBIO traded down $0.01 during trading on Wednesday, reaching $1.42. The company had a trading volume of 10,032 shares, compared to its average volume of 242,565. The company has a fifty day moving average of $3.85 and a two-hundred day moving average of $8.70. The stock has a market capitalization of $1.36 million, a P/E ratio of -0.02 and a beta of 1.82. Mustang Bio has a 12 month low of $1.35 and a 12 month high of $67.00.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.